



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

November 10, 2017

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Outcome of the Meeting of the Board of Directors - Unaudited Financial Results for the quarter ended on September 30, 2017.

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find unaudited financial results for the quarter ended on September 30, 2017 accompanied by limited review report. These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 12.00 noon and concluded at 1.20 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited

M. C. Mehta

Company Secretary and Vice President - Compliance

Encl: As above



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2017

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2017	30/06/2017	30/09/2016	30/09/2017	30/09/2016	31/03/2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	34,992.66	28,383.78	30,148.76	63,376.44	61,595.06	119,869.42
2	Other Income	696.15	927.18	1,464.53	1,623.33	2,543.71	4,589.03
3	Total Income (1+2)	35,688.81	29,310.96	31,613.29	64,999.77	64,138.77	124,458.45
4	Expenses						
	a. Cost of materials consumed	8,030.15	8,818.82	9,791.71	16,848.97	19,347.03	36,709.36
	b. Purchases of stock-in-trade	3,861.00	2,436.92	2,311.71	6,297.92	4,446.72	9,624.47
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,931.15	(134.24)	(691.02)	1,796.91	(865.08)	(1,805.26)
	d. Employees benefits expense	5,299.79	5,582.17	4,473.36	10,881.96	9,093.86	18,786.11
	e. Finance Costs	106.05	79.12	203.30	185.17	281.18	500.13
	f. Depreciation and amortization expense	1,432.71	1,432.84	1,118.33	2,865.55	2,250.00	4,626.42
	g. Other Expenses	8,233.05	8,573.34	8,247.02	16,806.39	16,617.85	34,338.86
	Total Expenses (4)	28,893.90	26,788.97	25,454.41	55,682.87	51,171.56	102,780.09
5	Profit before Tax (3-4)	6,794.91	2,521.99	6,158.88	9,316.90	12,967.21	21,678.36
6	Tax expenses	1,622.49	485.26	1,638.92	2,107.75	3,461.75	4,381.90
7	Net Profit/(Loss) after Tax and non controlling interest (5-6)	5,172.42	2,036.73	4,519.96	7,209.15	9,505.46	17,296.46
8	Other Comprehensive Income (net of Tax)	(13.08)	(67.61)	(8.07)	(80.69)	(16.14)	(270.43)
9	Total Comprehensive Income after Tax (7+8)	5,159.34	1,969.12	4,511.89	7,128.46	9,489.32	17,026.03
10	(1) Earning per share(EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	6.11	2.32	5.32	8.44	11.19	20.07
	(2) Diluted	6.11	2.32	5.32	8.44	11.19	20.07

Notes:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 10, 2017.
- The sales for the quarter ended on September 30, 2017 is net of GST. However, sales for the quarter ended on June 30, 2017 and quarter/half year ended on September 30, 2016 and year ended on March 31, 2017 are inclusive of excise duty. Thus, the sales during quarter/half year ended on September 30, 2017 are strictly not comparable.
- The auditors have carried out limited review of the financial results for the quarter ended on September 30, 2017 and their report does not contain any qualification.
- The Company has one reportable segment viz. Pharmaceuticals.
- The statement of assets and liabilities as at September 30, 2017 is as under:

(Rs. in lakhs)

Sl.No.	Particulars	As at September 30, 2017	As at March 31, 2017
	ASSETS		
(I)	Non-current assets		
	(a) Property, Plant and Equipment	57,128.43	59,366.61
	(b) Capital work-in-progress	1,716.32	376.25
	(c) Other Intangible assets	1,412.62	1,502.41
	(d) Financial Assets		
	(i) Investments	17,105.39	31,880.88
	(ii) Trade receivables	-	-
	(iii) Loans	21.49	30.43
	(iv) Others	658.74	648.77
	(e) Other non-current assets	836.06	330.76
	TOTAL non current assets	78,879.05	94,136.11



Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

(ii)	Current assets		
	(a) Inventories	14,472.47	15,995.57
	(b) Financial Assets		
	(i) Investments	38,793.17	22,496.16
	(ii) Trade receivables	26,650.21	26,509.52
	(iii) Cash and cash equivalents	1,197.02	719.71
	(iv) Loans	92.11	44.32
	(v) Others	117.47	95.57
	(c) Other current assets	9,831.17	8,440.31
	TOTAL current assets	91,153.62	74,301.16
	Total Assets	170,032.67	168,437.27
	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity Share capital	1,671.40	1,696.40
	(b) Other Equity	138,237.36	137,089.73
	Total Equity	139,908.76	138,786.13
	LIABILITIES		
(i)	Non-current liabilities		
	(a) Provisions	906.11	888.01
	(b) Deferred tax liabilities (Net)	2,834.60	2,895.35
	(c) Other non-current liabilities	412.19	395.48
	TOTAL non current Liabilities	4,152.90	4,178.84
(ii)	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	5,108.92	4,886.03
	(ii) Trade payables	6,165.03	7,903.47
	(iii) Other financial liabilities	12,138.63	10,977.95
	(b) Other current liabilities	1,021.02	830.07
	(c) Provisions	1,006.79	787.39
	(d) Current Tax Liabilities (Net)	530.62	87.39
	TOTAL Current Liabilities	25,971.01	25,472.30
	Total Equity and Liabilities	170,032.67	168,437.27

6. The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.


J.B. Mody
Chairman & Managing Director

Place : Mumbai
Date : 10/11/2017



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380

Limited Review Report on quarterly Unaudited Standalone Financial Results of J. B. Chemicals and Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors of
J. B. Chemicals and Pharmaceuticals Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results ('the Statement') of **J. B. Chemicals and Pharmaceuticals Limited** ('the Company'), for the quarter and six months period ended September 30, 2017 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on November 10, 2017. Our responsibility is to issue a Report on this Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' ('the Standard'), issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Other Matter:

4. The comparative figures for the quarter ended June 30, 2017, quarter and six months period ended September 30, 2016 and the year ended March 31, 2017 prepared in accordance with applicable Indian Accounting Standards ('Ind AS') were reviewed / audited by the erstwhile auditors who had expressed unmodified limited review/ audit opinion on these financial results/ financial statements vide their reports dated August 11, 2017, November 18, 2016 and May 23, 2017 respectively.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Standalone Financial Results prepared in accordance with applicable Ind AS prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Damania & Varaiya

Chartered Accountants


Firm Registration No.: 102079W



CA Bharat Jain

Partner

Membership No.: 100583



Place: Mumbai

Date: November 10, 2017



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2017

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2017	30/06/2017	30/09/2016	30/09/2017	30/09/2016	31/03/2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	34,992.66	28,383.78	30,148.76	63,376.44	61,595.06	119,869.42
2	Other Income	696.15	927.18	1,464.53	1,623.33	2,543.71	4,589.03
3	Total Income (1+2)	35,688.81	29,310.96	31,613.29	64,999.77	64,138.77	124,458.45
4	Expenses						
	a. Cost of materials consumed	8,030.15	8,818.82	9,791.71	16,848.97	19,347.03	36,709.36
	b. Purchases of stock-in-trade	3,861.00	2,436.92	2,311.71	6,297.92	4,446.72	9,624.47
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,931.15	(134.24)	(691.02)	1,796.91	(865.08)	(1,805.26)
	d. Employees benefits expense	5,299.79	5,582.17	4,473.36	10,881.96	9,093.86	18,786.11
	e. Finance Costs	106.05	79.12	203.30	185.17	281.18	500.13
	f. Depreciation and amortization expense	1,432.71	1,432.84	1,118.33	2,865.55	2,250.00	4,626.42
	g. Other Expenses	8,233.05	8,573.34	8,247.02	16,806.39	16,617.85	34,338.86
	Total Expenses (4)	28,893.90	26,788.97	25,454.41	55,682.87	51,171.56	102,780.09
5	Profit before Tax (3-4)	6,794.91	2,521.99	6,158.88	9,316.90	12,967.21	21,678.36
6	Tax expenses	1,622.49	485.26	1,638.92	2,107.75	3,461.75	4,381.90
7	Net Profit/(Loss) after Tax and non controlling interest (5-6)	5,172.42	2,036.73	4,519.96	7,209.15	9,505.46	17,296.46
8	Other Comprehensive Income (net of Tax)	(13.08)	(67.61)	(8.07)	(80.69)	(16.14)	(270.43)
9	Total Comprehensive Income after Tax (7+8)	5,159.34	1,969.12	4,511.89	7,128.46	9,489.32	17,026.03
10	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	6.11	2.32	5.32	8.44	11.19	20.07
	(2) Diluted	6.11	2.32	5.32	8.44	11.19	20.07

Notes:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 10, 2017.
- The sales for the quarter ended on September 30, 2017 is net of GST. However, sales for the quarter ended on June 30, 2017 and quarter/half year ended on September 30, 2016 and year ended on March 31, 2017 are inclusive of excise duty. Thus, the sales during quarter/half year ended on September 30, 2017 are strictly not comparable.
- The auditors have carried out limited review of the financial results for the quarter ended on September 30, 2017 and their report does not contain any qualification.
- The Company has one reportable segment viz. Pharmaceuticals.
- The statement of assets and liabilities as at September 30, 2017 is as under:

(Rs. in lakhs)

Sl.No.	Particulars	As at September 30, 2017	As at March 31, 2017
	ASSETS		
(i)	Non-current assets		
	(a) Property, Plant and Equipment	57,128.43	59,366.61
	(b) Capital work-in-progress	1,716.32	376.25
	(c) Other Intangible assets	1,412.62	1,502.41
	(d) Financial Assets		
	(i) Investments	17,105.39	31,880.88
	(ii) Trade receivables	-	-
	(iii) Loans	21.49	30.43
	(iv) Others	658.74	648.77
	(e) Other non-current assets	836.06	330.76
	TOTAL non current assets	78,879.05	94,136.11



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

(II)	Current assets		
	(a) Inventories	14,472.47	15,995.57
	(b) Financial Assets		
	(i) Investments	38,793.17	22,496.16
	(ii) Trade receivables	26,650.21	26,509.52
	(iii) Cash and cash equivalents	1,197.02	719.71
	(iv) Loans	92.11	44.32
	(v) Others	117.47	95.57
	(c) Other current assets	9,831.17	8,440.31
	TOTAL current assets	91,153.62	74,301.16
	Total Assets	170,032.67	168,437.27
	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity Share capital	1,671.40	1,696.40
	(b) Other Equity	138,237.36	137,089.73
	Total Equity	139,908.76	138,786.13
	LIABILITIES		
(I)	Non-current liabilities		
	(a) Provisions	906.11	888.01
	(b) Deferred tax liabilities (Net)	2,834.60	2,895.35
	(c) Other non-current liabilities	412.19	395.48
	TOTAL non current Liabilities	4,152.90	4,178.84
(II)	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	5,108.92	4,886.03
	(ii) Trade payables	6,165.03	7,903.47
	(iii) Other financial liabilities	12,138.63	10,977.95
	(b) Other current liabilities	1,021.02	830.07
	(c) Provisions	1,006.79	787.39
	(d) Current Tax Liabilities (Net)	530.62	87.39
	TOTAL Current Liabilities	25,971.01	25,472.30
	Total Equity and Liabilities	170,032.67	168,437.27

6. The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J. B. Chemicals & Pharmaceuticals Ltd.


J.B. Mody
Chairman & Managing Director

Place : Mumbai
Date : 10/11/2017



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380